Survival data boosts Merck's Keytruda lead in lung cancer
(Reuters) - Merck& Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market. (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Lung Cancer Patients Live Longer With Immune Therapy
Adding immunotherapy to standard chemo treatments can halve the risk of death for people with the most common type of lung cancer, a new study shows. (Source: NYT Health)
Source: NYT Health - April 16, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Immune System Lung Cancer Immunotherapy Chemotherapy American Assn for Cancer Research Merck & Company Inc Source Type: news

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials
(Reuters) - Merck& Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market. (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck lung cancer trial boosts immunotherapy hopes
Company says test results show ‘unambiguous’ improvement in survival rates  (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 16, 2018 Category: Pharmaceuticals Source Type: news

Adding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients
Another study combined Opdivo and Yervoy, two drugs made by Bristol-Myers Squibb, in lung cancer patients selected with a new type of diagnostic test. An third result hints that giving Opdivo earlier – before surgery to remove tumors – may lead to even more benefits for patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 16, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:MRK NYSE:BMY Source Type: news

Mylan seeks deal for German Merck's consumer products unit: sources
FRANKFURT/NEW YORK (Reuters) - Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said. (Source: Reuters: Health)
Source: Reuters: Health - April 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Livongo raises $105m for digital diabetes management platform
Livongo Health closed a $105 million round led by a group of investors including General Catalyst, Merck Global Health Innovation Fund and Echo Health Ventures. The Mountain View, Calif.-based company has developed Livongo for Diabetes – a collection of connected devices that enable people with diabetes to interact with a virtual care team. Get the full story at our sister site, Drug Delivery Business News. The post Livongo raises $105m for digital diabetes management platform appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup Patient Monitoring Software / IT Livongo Source Type: news

Is IO Monotherapy the New Standard of Care in Advanced NSCLC? Is IO Monotherapy the New Standard of Care in Advanced NSCLC?
Merck has released provocative but limited findings from the KEYNOTE-042 trial that indicate better outcomes for first-line pembrolizumab vs standard chemotherapy in advanced non-small cell lung cancer (NSCLC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

GSK to Compensate for Merck's Pediatric HepB Vaccine Shortage
In the face of a continuing shortage of Merck's pediatric hepatitis B vaccines, the CDC says GlaxoSmithKline will fill in with sufficient supply to meet full U.S. demand. (Source: AAFP News)
Source: AAFP News - April 11, 2018 Category: Primary Care Source Type: news

Merck eyes best day since 2016, gains help fuel pharma rally
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 9, 2018 Category: Pharmaceuticals Source Type: news

Incyte's trial fails to boost Keytruda to treat melanoma
Incyte has scrapped plans for a drug to boost the effectiveness of Merck's Keytruda to treat skin cancer patients after a Phase 3 clinical trial failed. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 9, 2018 Category: Consumer Health News Source Type: news

Merck's Keytruda helps lung cancer patients live longer in trial
(Reuters) - Merck& Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market. (Source: Reuters: Health)
Source: Reuters: Health - April 9, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck's Keytruda meets main goal in pivotal lung cancer trial
(Reuters) - Merck& Co said on Monday a late-stage trial testing its blockbuster cancer drug, Keytruda, met the main goal of helping previously untreated lung cancer patients live longer, sending its shares up 3 percent in premarket trade. (Source: Reuters: Health)
Source: Reuters: Health - April 9, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Melanoma trial failure deals heavy blow to immunotherapy hopes
Merck slides and Incyte loses $4bn market value as ‘combination’ cancer study flops (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 6, 2018 Category: Pharmaceuticals Source Type: news

Incyte stock plummets following disappointing clinical study results
Incyte Corp. ’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy. The results from a phase-III clinical study, testing Incyte’s new drug candidate epacadostat with Merck& Co. Inc. ’s immunotherapy drug Keytruda, found the combination therapy did not improve progression-free survival in patients with metastatic melanoma, a type of skin cancer. Incyte and Merck said, at… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 6, 2018 Category: Health Management Authors: John George Source Type: news

Incyte, Merck melanoma combo therapy fails study, shares slide
(Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck& Co's Keytruda failed to meet the main goal in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Incyte's combo therapy for skin cancer fails in late-stage study
(Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug in combination with Merck& Co's Keytruda for a type of skin cancer failed to meet the main goal in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Report: Pharma companies ask Supremes to take eye-dropper case
A group of pharmaceutical companies, including Allergan (NYSE:AGN) and Merck (NYSE:MRK), have asked the Supreme Court to review a case between the industry players and patients regarding the design of the companies’ eye-droppers, according to a report from the AP. In the on-going legal debate, patient groups have claimed that the companies’ devices dispense large drops of medication that overwhelm the eye and ultimately waste expensive drug product. The users also allege that if the bottle was properly designed to dispense smaller drops of medicine, they would pay less. Get the full story at our ...
Source: Mass Device - April 2, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Merck Source Type: news

Myriad ’ s breast cancer diagnostic wins approval in Japan
Myriad Genetics (NSDQ:MYGN) subsidiary Myriad Genetics Laboratories said today that the Japanese Ministry of Health, Labor & Welfare approved its Bracanalysis Diagnostic System to be used with Lynparza – a breast cancer drug marketed by AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK). Lynparza is a PARP inhibitor designed to target deficiencies in DNA damage response pathways. AstraZeneca and Merck are working to get the drug cleared in Japan to treat patients with BRCA-mutated metastatic breast cancer. Myriad’s Bracanalysis test is the first test approved in Japan for use with a PARP i...
Source: Mass Device - April 2, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diagnostics Food & Drug Administration (FDA) Oncology Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Merck Myriad Genetics Inc. Source Type: news

Merck, National Sleep Foundation to launch new Fitbit-powered study
Physicians have touted the benefits of a good night ’s sleep for centuries, if not longer, but it hasn’t been until recent years that a provider can see clear data on whether or not their patients have been hitting the sack. (Source: mobihealthnews)
Source: mobihealthnews - March 29, 2018 Category: Information Technology Source Type: news

Merck partners with Medisafe to help improve medication adherence for cardiometabolic patients
Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens. In the countries of scope Merck patients will have access to a customized version of Medisafe's mobile platform that could combine reminders, motivation and support systems, targeted content, coupons and interventions in their local language. (Source: World Pharma News)
Source: World Pharma News - March 28, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Pembrolizumab Promising in Previously Treated Gastric Cancer Pembrolizumab Promising in Previously Treated Gastric Cancer
In patients with advanced gastric or gastro-esophageal cancer progressing after second-line treatment, monotherapy with pembrolizumab offers a “ promising new treatment option, ” according to research from Merck, which sells the drug as Keytruda.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Merck Partners with Medisafe to Help Improve Medication Adherence for Cardiometabolic Patients
Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens. In the countries of scope Merck patients will have access to a customized version of Medisafe's mobile platform that could combine reminders, motivation and support systems, targeted content, coupons and interventions in their local language. (Source: eHealth News EU)
Source: eHealth News EU - March 27, 2018 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

Merck appoints Milind Thatte as MD
He heads the leadership team of healthcare sector and is the member of the country council of Merck India, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 27, 2018 Category: Pharmaceuticals Source Type: news

Roche's Tecentriq cocktail adds to lung cancer survival success
ZURICH (Reuters) - Roche's Tecentriq immunotherapy combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb. (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Tecentriq cocktail notches another lung cancer success
ZURICH (Reuters) - Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company's latest trial success as it seeks an edge on Merck and Bristol-Myers Squibb. (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Tecentriq notches third cancer cocktail trial win
ZURICH (Reuters) - Roche's immunotherapy Tecentriq on Tuesday racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drugmaker as it seeks to muscle in on space dominated by Merck and Bristol-Myers Squibb. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Blue Cross executive featured in Savoy's '2018 Most Influential Blacks in Corporate America'
Savoy Magazine has named Cain Hayes, president and chief operating officer of Blue Cross and Blue Shield of Minnesota's health business, as one of its "2018 Most Influential Blacks in Corporate America." Hayes joins the likes of "Black Panther" star Chadwick Bosman and Kenneth Frazier, CEO and chairman of biopharmaceutical manufacturer Merck& Co. Inc., as leaders to grace the covers of Savoy's spring edition. "I am honored to represent Blue Cross and Blue Shield of Minnesota on this esteemed… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 19, 2018 Category: Health Management Authors: Haley Madderom Source Type: news

Blue Cross executive featured in Savoy's '2018 Most Influential Blacks in Corporate America'
Savoy Magazine has named Cain Hayes, president and chief operating officer of Blue Cross and Blue Shield of Minnesota's health business, as one of its "2018 Most Influential Blacks in Corporate America." Hayes joins the likes of "Black Panther" star Chadwick Bosman and Kenneth Frazier, CEO and chairman of biopharmaceutical manufacturer Merck& Co. Inc., as leaders to grace the covers of Savoy's spring edition. "I am honored to represent Blue Cross and Blue Shield of Minnesota on this esteemed… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 19, 2018 Category: Biotechnology Authors: Haley Madderom Source Type: news

Mass. Supremes: Pharma Cos. liable for generic labeling issues
Merck (NYSE:MRK) and other large brand-name pharmaceutical manufacturers could be legally liable for injuries resulting not from the use of their brand name products, but from generic versions of those drugs made by other companies, according to a new ruling from the Massachusetts Supreme Judicial Court. The court ruling could set the precedent that such brand-name pharma companies could be found liable for reckless behavior if they fail to update labeling for their products which are also used for generic versions, according to court documents. Read the whole story on our sister site, Drug Delivery Business The post ...
Source: Mass Device - March 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Legal News Pharmaceuticals Merck Source Type: news

Massachusetts court: Merck can be sued over generic drug injury
BOSTON (Reuters) - Massachusetts' top court on Friday opened the door for consumers to sue Merck& Co Inc and other makers of brand-name drugs over injuries blamed not on their own medications but on generic versions of their treatments made by other companies. (Source: Reuters: Health)
Source: Reuters: Health - March 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Claire ’s Filing for Bankruptcy After Asbestos Found in Makeup
Claire’s, a fashion accessory retail chain marketed to young girls and preteens, is reportedly filing for bankruptcy as a second round of lab tests found deadly asbestos fibers in the store’s cosmetics products. Bloomberg News reported last week that Claire’s Stores Inc. plans to file for bankruptcy in the coming weeks to ease the $2 million debt load. The deal would transfer control from Apollo Global Management LLC to lenders, including Elliott Capital Management and Monarch Alternative Capital. U.S. PIRG, a consumer and public interest research group, released a report Tuesday revealing three Claire&r...
Source: Asbestos and Mesothelioma News - March 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

The Strategic Investor Initiative's Third CEO Investor Forum
On February 26, 2018 the CEOs of Johnson& Johnson, Medtronic, Merck, Unilever, and UPS presented their long-term plans to an audience of institutional investors representing $25 trillion in assets under management at the CECP Strategic Investor Initiative's Third CEO Investor Forum. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 11, 2018 Category: Pharmaceuticals Authors: Dr. Bob Eccles, Contributor Source Type: news

Germany's Merck Seeks Drug Development Partners Germany's Merck Seeks Drug Development Partners
German drugs and chemicals group Merck KGaA is open to sharing development costs for its mid-stage pharmaceuticals pipeline with external partners, it said on Thursday after flagging a decline in earnings this year.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Eisai Clinches Merck Deal to Develop and Sell Cancer Drug, Shares Soar Eisai Clinches Merck Deal to Develop and Sell Cancer Drug, Shares Soar
Merck& Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Eisai/Merck: doubling up, and down
Japanese group’s tie-up with US pharma on cancer drug will boost its research on Alzheimer’s (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 8, 2018 Category: Pharmaceuticals Source Type: news

Eisai clinches Merck deal to develop and sell cancer drug, shares soar
NEW YORK/TOKYO (Reuters) - Merck& Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses. (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck, Eisai in deal to further develop, sell Eisai cancer drug
NEW YORK (Reuters) - Merck& Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses. (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Big Pharma's contradictory JUNK SCIENCE: Merck pulls "promising" Alzheimer’s drug from trials the same day Cleveland Clinic hails its success
(Natural News) Testing on what drug giant Merck & Co. had tried to claim was going to be a breakthrough new remedy for Alzheimer’s disease came to a sudden halt recently after it was determined that the drug in question actually doesn’t work at all. But interestingly enough, the trial’s cessation occurred on the very... (Source: NaturalNews.com)
Source: NaturalNews.com - March 8, 2018 Category: Consumer Health News Source Type: news

Merck, Eisai sign deal to further develop, sell Eisai cancer drug
(Reuters) - Merck& Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many countries for two uses. (Source: Reuters: Health)
Source: Reuters: Health - March 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government and Public Affairs
ROCKLAND, Mass., March 6, 2018 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that Wendy Sussman has joined the organization as Vice Preside... Biopharmaceuticals, Personnel EMD Serono, Merck KGaA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 6, 2018 Category: Pharmaceuticals Source Type: news

Why Flu Outbreaks Have Been the Worst in Nearly a Decade
The only thing worse than getting the flu is catching it after you’ve gotten a flu shot. It’s been a terrible year for outbreaks — the worst in almost a decade. Contributing to that is the high failure rate of this year’s vaccine. The current shot is just 25 percent effective against the H3N2 virus, this season’s most-often-identified strain by the Centers for Disease Control and Prevention. The experts say, with enough time and money, they can do a lot better. “There has to be a wholesale change to how we make the flu vaccine,” said Amesh Adalja, senior scholar at Johns Hopkins Ce...
Source: TIME: Science - February 28, 2018 Category: Science Authors: Bloomberg Tags: Uncategorized Bloomberg flu healthytime onetime Source Type: news

CDC Director Resigns Amid Reports of Tobacco Stock Trade
The Department of Health and Human Services (HHS) announced on January 31, 2018, that Dr. Brenda Fitzgerald would resign as the Director of the Centers for Disease Control and Prevention (CDC). The statement read, “Dr. Fitzgerald owns certain complex financial interests that have imposed a broad recusal limiting her ability to complete all of her duties as the CDC Director. Due to the nature of these financial interests, Dr. Fitzgerald could not divest from them in a definitive time period.” The decision came a day after Politico reported that she bought stock in a large tobacco company within a month of start...
Source: Public Policy Reports - February 23, 2018 Category: Biology Authors: AIBS Source Type: news

Merck to Buy Australian Viral Immuno-oncology Firm for $394 Million Merck to Buy Australian Viral Immuno-oncology Firm for $394 Million
U.S. drugmaker Merck& Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 22, 2018 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Gilead Wins Reversal of $2.54 Bln Hepatitis C Drug Patent Verdict Gilead Wins Reversal of $2.54 Bln Hepatitis C Drug Patent Verdict
A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck& Co Inc.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Merck and three partners start ExploreBio, a € 20 million pre-seed investment initiative in Israel
Merck, a leading science and technology company, today announced ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel. For this purpose the strategic corporate venture capital arm of Merck has partnered with Arkin Holdings, Pontifax and WuXi AppTec to create the € 20 million pre-seed investment vehicle. (Source: World Pharma News)
Source: World Pharma News - February 20, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
(Reuters) - A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck& Co Inc. (Source: Reuters: Health)
Source: Reuters: Health - February 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial
FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. (Source: Reuters: Health)
Source: Reuters: Health - February 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Cambridge biotech startup seeking to repurpose Vioxx raises $5M
Tremeau Pharmaceuticals, a Cambridge biotech startup that is seeking to repurpose the controversial Merck& Co. arthritis drug Vioxx as a treatment for joint pain caused by hemophilia, has closed its first equity round. Tremeau, which was founded last year, announced Thursday that it has raised $5.2 million in equity financing, although it did not disclose the investors that participated. The six-employee company said the funding would be used to advance the drug — whose generic name is rofecoxib… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 15, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Why Merck's Provata acquisition could portend more health care M & A
Look for increased deal activity as investors hunt for promising health IT startups and drugmakers look for ways to reduce overall health care costs as public scrutiny intensifies. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 14, 2018 Category: American Health Authors: Elizabeth Hayes Source Type: news